Your browser doesn't support javascript.
loading
Occurrence and severity of cocaine-induced hallucinations: Two distinct phenotypes with shared clinical factors but specific genetic risk factors.
Zerdazi, El-Hadi; Curis, Emmanuel; Karsinti, Emily; Icick, Romain; Fortias, Maeva; Batel, Philippe; Cottencin, Olivier; Orizet, Cyrille; Gay, Aurélia; Coeuru, Philippe; Deschenau, Alice; Lack, Philippe; Moisan, Delphine; Pelissier-Alicot, Anne-Laure; Plat, Arnaud; Trabut, Jean-Baptiste; Kousignian, Isabelle; Boumendil, Luana; Vicaut, Eric; Prince, Nathalie; Laplanche, Jean-Louis; Bellivier, Frank; Lépine, Jean-Pierre; Marie-Claire, Cynthia; Brousse, Georges; Vorspan, Florence; Bloch, Vanessa.
Afiliação
  • Zerdazi EH; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, Hôpitaux Universitaires Henri Mondor, DMU IMPACT, Hôpital Emile ROUX, Service d'addictologie, Limeil Brévannes 94450, France. Electronic address: el-hadi.zerdazi@inserm.f
  • Curis E; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; EA 7537 BioSTM, Faculté de Pharmacie, Université Paris Descartes, USPC, Paris 75006, France.
  • Karsinti E; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France; Université Paris Nanterre, Laboratoire
  • Icick R; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France.
  • Fortias M; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France.
  • Batel P; Centre Hospitalier Camille Claudel, Service d'Addictologie de la Charente, La Couronne 16400, France.
  • Cottencin O; University of Lille, Inserm U-1172, CHU Lille, Department of Psychiatry and Addiction Medicine, Lille 59000, France.
  • Orizet C; APHP, GHU Centre-Université de Paris, Hôpital Européen Georges Pompidou, CSAPA Monte-Cristo, Paris 75015, France.
  • Gay A; CHU Saint-Etienne, Service d'Addictologie, Saint-Etienne 42000, France.
  • Coeuru P; Association Aurore, CSAPA EGO, Paris 75018, France.
  • Deschenau A; Hôpital Paul Guiraud, CSAPA Clinique Liberté, Ivry-sur-Seine 94200, France.
  • Lack P; Hôpital de la Croix Rousse, CSAPA, Lyon 69004, France.
  • Moisan D; APHP, GHU Nord-Université de Paris, Hôpital Beaujon, UTAMA, Clichy 92110, France.
  • Pelissier-Alicot AL; APHM, CHU La Timone, Service de Médecine légale, Aix-Marseille Université, Faculté de Médecine, Marseille 13385, France.
  • Plat A; APHP, GHU Nord-Université de Paris, Hôpital Beaujon, UTAMA, Clichy 92110, France.
  • Trabut JB; APHP, Hôpitaux Universitaires Henri Mondor, DMU IMPACT, Hôpital Emile ROUX, Service d'addictologie, Limeil Brévannes 94450, France.
  • Kousignian I; EA 7537 BioSTM, Faculté de Pharmacie, Université Paris Descartes, USPC, Paris 75006, France.
  • Boumendil L; EA 7537 BioSTM, Faculté de Pharmacie, Université Paris Descartes, USPC, Paris 75006, France.
  • Vicaut E; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Unité de Recherche Clinique, Paris 75010, France.
  • Prince N; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France.
  • Laplanche JL; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Lariboisière, DMU BioGeM, Département de Biochimie et Biologie Moléculaire, Paris 75010, France.
  • Bellivier F; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France.
  • Lépine JP; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France.
  • Marie-Claire C; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France.
  • Brousse G; CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Service d'Addictologie et Université d'Auvergne EA 7280, UFR de Médecine, Clermont-Ferrand 63000, France.
  • Vorspan F; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Département de Psychiatrie et de Médecine Addictologigue, Paris 75010, France.
  • Bloch V; Université de Paris, INSERM UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie OTeN, Paris F-75006, France; APHP, GHU Nord-Université de Paris, Hôpital Fernand Widal, Pharmacie Hospitalière, Paris 75010, France.
Drug Alcohol Depend ; 232: 109270, 2022 03 01.
Article em En | MEDLINE | ID: mdl-35124387
Cocaine-induced transient hallucinations (CIH) are a frequent complication following cocaine intake that is associated with addiction severity. METHODS: Two hundred and forty-two non-psychotic and Caucasian lifetime cocaine users were included in a French multicentric study. Clinical variables and dopamine pathway genotype data were extracted and tested with CIH scores using a zero-inflated binomial model, which allows for the exploration of factors associated with occurrence and severity separately. RESULTS: Cocaine dependence (poccurrence= 6.18 × 10-5, pseverity= 9.25 × 10-8), number of cocaine dependence DSM IV-Tr criteria (poccurrence= 1.22 × 10-7, pseverity= 5.09 × 10-6), and frequency of intake during the worst period of misuse (poccurrence= 8.51 × 10-04, pseverity= 0.04) were associated with greater occurrence and higher severity of CIH. The genetic associations did not yield significant results after correction for multiple tests. However, some nominal associations of SNPs mapped to the VMAT2, DBH, DRD1, and DRD2 genes were significant. In the multivariate model, the significant variables were the number of cocaine dependence criteria, lifetime alcohol dependence, and the nominally associated SNPs. CONCLUSION: Our study shows that CIH occurrence and severity are two distinct phenotypes, with shared clinical risk factors; however, they likely do not share the same genetic background.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cocaína / Transtornos Relacionados ao Uso de Cocaína Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cocaína / Transtornos Relacionados ao Uso de Cocaína Idioma: En Ano de publicação: 2022 Tipo de documento: Article